Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Glaxo abacavir ("1592") compassionate use program for pediatric AIDS to be launched in June.

Executive Summary

GLAXO ABACAVIR EXPANDED ACCESS PROGRAM IN PEDIATRIC AIDS TO BEGIN IN JUNE, the company told HIV/ AIDS groups in a recent letter. A reverse transcriptase inhibitor, abacavir (1592U89) is in Phase III trials, with an NDA filing expected in 1998. In July, Glaxo Wellcome plans to launch two additional compassionate use programs: for people with severe AIDS Dementia Complex (ADC) and for the adult AIDS population. A broader program is planned for early 1998. The initiatives will run concurrently with controlled clinical trials, the letter states.

Latest Headlines
See All
UsernamePublicRestriction

Register

PS030172

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel